scholarly journals Thalidomide as Therapy for Human Immunodeficiency Virus‐Related Oral Ulcers: A Double‐Blind Placebo‐Controlled Clinical Trial

1999 ◽  
Vol 28 (4) ◽  
pp. 892-894 ◽  
Author(s):  
Velia A. Ramirez‐Amador ◽  
Lilly Esquivel‐Pedraza ◽  
Sergio Ponce‐de‐Leon ◽  
Gustavo Reyes‐Teran ◽  
Martha Gonzalez‐Guevara ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Human Immunodeficiency Virus ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Oral Ulcers ◽  
Immunodeficiency Virus

scholarly journals Sorivudine versus Acyclovir for Treatment of Dermatomal Herpes Zoster in Human Immunodeficiency Virus-Infected Patients: Results from a Randomized, Controlled Clinical Trial

1998 ◽  
Vol 42 (5) ◽  
pp. 1139-1145 ◽  
Author(s):  
John W. Gnann ◽  
Clyde S. Crumpacker ◽  
Jacob P. Lalezari ◽  
Jean A. Smith ◽  
Stephen K. Tyring ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Human Immunodeficiency Virus ◽  
Herpes Zoster ◽  
Univariate Analysis ◽  
Controlled Clinical Trial ◽  
Vesicle Formation ◽  
Double Blind ◽  
Viral Culture ◽  
Immunodeficiency Virus ◽  
Hiv Seropositive

The present randomized, double-blind, placebo-controlled, multicenter clinical trial was designed to compare the efficacy and tolerability of sorivudine [1-β-d-arabinofuranosyl-E-(2-bromovinyl)uracil] and acyclovir for the treatment of dermatomal herpes zoster in human immunodeficiency virus (HIV)-seropositive patients. A total of 170 HIV-seropositive adults presenting with herpes zoster (confirmed by direct fluorescent-antigen testing and/or viral culture) were enrolled and randomized to receive a 10-day course of orally administered sorivudine (40 mg once daily plus acyclovir placebos) or acyclovir (800 mg five times daily plus sorivudine placebo). Patients were monitored daily to document the events of cutaneous healing, pain, zoster-related complications, and drug-related adverse events. Patients were reassessed on days 21 and 28 and then once monthly for 1 year. The primary efficacy endpoint was time to the cessation of new vesicle formation. Secondary efficacy endpoints included times to other events of cutaneous healing, resolution of pain, and frequency of dissemination and zoster recurrence. In a multivariate analysis, sorivudine was superior to acyclovir for reducing the times to the cessation of new vesicle formation (relative risk [RR] = 1.54, 95% confidence interval [CI] = 1.00 to 2.36; P = 0.049) and total lesion crusting (RR = 1.48, 95% CI = 1.07 to 2.04;P = 0.017). In a univariate analysis, there was a trend favoring sorivudine for the cessation of new vesicle formation (median of 3 versus 4 days; P = 0.07) and a significant advantage for time to total lesion crusting (median of 7 versus 8 days; P = 0.02). The time to the resolution of zoster-associated pain, the frequency of dissemination, and the frequency of zoster recurrence were not different between the two treatment groups. Both drugs were well tolerated. Sorivudine is an effective drug for the treatment of herpes zoster in HIV-infected patients and results in accelerated cutaneous healing when compared with acyclovir therapy.

Double blind placebo controlled clinical trial of homoeopathic medicines in HIV infection

1998 ◽  
Vol 87 (2) ◽  
pp. 86-88
Author(s):  
D P Rastogi ◽  
V P Singh ◽  
Vikram Singh ◽  
S K Dey ◽  
K Rao
Keyword(s):  
Clinical Trial ◽  
Hiv Infection ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

Significant immunomodulatory and hepatoprotective impacts of Silymarin in MS patients: A double-blind placebo-controlled clinical trial

2021 ◽  
Vol 97 ◽  
pp. 107715
Author(s):  
Faezeh Abbasirad ◽  
Vahid Shaygannejad ◽  
Fahimeh Hosseininasab ◽  
Omid Mirmosayyeb ◽  
Behzad Mahaki ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

Effects of creatine supplementation on renal function: a randomized, double-blind, placebo-controlled clinical trial

2008 ◽  
Vol 103 (1) ◽  
pp. 33-40 ◽  
Author(s):  
Bruno Gualano ◽  
Carlos Ugrinowitsch ◽  
Rafael Batista Novaes ◽  
Guilherme Gianini Artioli ◽  
Maria Heloisa Shimizu ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Renal Function ◽  
Creatine Supplementation ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

Effectiveness of the piperine-supplemented Curcuma longa L. in metabolic control of patients with type 2 diabetes: a randomised double-blind placebo-controlled clinical trial

2021 ◽  
pp. 1-10
Author(s):  
Joana Furtado de Figueiredo Neta ◽  
Vivian Saraiva Veras ◽  
Danilo Ferreira de Sousa ◽  
Maria da Conceição dos Santos Oliveira Cunha ◽  
Maria Veraci Oliveira Queiroz ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Metabolic Control ◽  
Curcuma Longa ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document